Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

By D. Montani, E. Bergot, S. Günther, L. Savale, A. Bergeron, A. Bourdin, H. Bouvaist, M. Canuet, C. Pison, M. Macro and 12 more. Circulation, 2012

606 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/db3b06f8d21b3c8a2cdf7c57b54b2ce7146b6d43

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. T. Marwick
2. G. Simonneau

Citations in the corpus

• Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “This is particularly important in patients treated with dasatinib, a tyrosine kinase inhibitor, as pulmonary arterial hypertension may be a specific complication.(54)”
• Pulmonary arterial hypertension (2013, background): “As described above, dasatinib use may be one cause of PAH, particularly in chronic myeloid leukemia [23].”